Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to -$246.3 million.

  • Rhythm Pharmaceuticals' Cash from Investing Activities fell 17125.35% to -$246.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$146.3 million, marking a year-over-year decrease of 21343.54%. This contributed to the annual value of -$48.2 million for FY2024, which is 75036.19% down from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Cash from Investing Activities stood at -$246.3 million for Q3 2025, which was down 17125.35% from $54.0 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $72.5 million during Q1 2022, with a 5-year trough of -$246.3 million in Q3 2025.
  • Moreover, its 5-year median value for Cash from Investing Activities was $18.5 million (2023), whereas its average is -$13.4 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 66256.9% in 2022, then skyrocketed by 73110.25% in 2025.
  • Rhythm Pharmaceuticals' Cash from Investing Activities (Quarter) stood at $7.2 million in 2021, then tumbled by 662.57% to -$40.8 million in 2022, then surged by 155.52% to $22.6 million in 2023, then fell by 6.55% to $21.2 million in 2024, then tumbled by 1264.38% to -$246.3 million in 2025.
  • Its last three reported values are -$246.3 million in Q3 2025, $54.0 million for Q2 2025, and $24.8 million during Q1 2025.